Skip to main content
. 2022 Dec 29;13(1):100. doi: 10.3390/life13010100

Figure 2.

Figure 2

Effect of ALS-L1023 on fibrosis and Non-alcoholic fatty liver disease (NAFLD) Activity score in the liver. (A) Liver Sirius stain and area of fibrosis (%), 50×, 100×. (B) Liver H&E stain and NAFLD Activity score, 50×, 100×. Data are presented as mean ± standard deviation and were analyzed by one-way ANOVA. * p < 0.05, *** p < 0.001, **** p < 0.0001 compared to the choline-deficient high-fat (CDHF) group. Obeticholic acid (OCA) was used as a positive control.